Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

The pharma will vie for amlitelimab’s approval, despite the COAST 2 trial missing a co-primary endpoint.

NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...